Barinthus Biotherapeutics PLC 8-K filings

Barinthus Biotherapeutics reported Q2 2026 results, highlighting progress in its celiac disease trial and a proposed merger with Clywedog Therapeutics, while also addressing Nasdaq listing compliance.

Barinthus Biotherapeutics PLC announces successful shareholder votes at its 2026 Annual General Meeting and secures an extended deadline until December 28, 2026, to regain Nasdaq's minimum bid price requirement.

Barinthus Biotherapeutics plc announces overwhelming shareholder approval for its Scheme of Arrangement, paving the way for a significant corporate transaction.

Barinthus Bio announced Q1 2026 financial results, highlighting progress on its merger with Clywedog Therapeutics and the ongoing Phase 1 AVALON trial for VTP-1000 in celiac disease.

Barinthus Biotherapeutics has appointed Douglas Swirsky as Chief Financial Officer and principal accounting officer, effective May 1, 2026.

Barinthus Biotherapeutics plc announced that Gemma Jones will step down as Principal Accounting Officer, effective April 30, 2026.

Barinthus Biotherapeutics announced its 2025 financial results, progress in its celiac disease trial, and reaffirmed its planned merger with Clywedog Therapeutics, expected to close in Q2 2026.

Barinthus Biotherapeutics and Clywedog Therapeutics amend their merger agreement, adjusting exchange ratios and minimum cash requirements due to unexpected transaction delays.

Barinthus Biotherapeutics plc received a Nasdaq notice for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

Barinthus Biotherapeutics announced positive initial safety and dose-dependent pharmacological effects for VTP-1000 in the SAD portion of its Phase 1 AVALON trial for celiac disease.

Barinthus Biotherapeutics announced its third-quarter 2025 financial results and provided updates on its proposed all-stock merger with Clywedog Therapeutics Inc., aiming to diversify its pipeline and extend its cash runway.

Barinthus Biotherapeutics and Clywedog Therapeutics announce an all-stock merger to create a combined company focused on metabolic and autoimmune diseases, with key clinical milestones expected within 18 months.

Barinthus Biotherapeutics amends its prior 8-K filing to correct a statement regarding its VTP-850 trial and reports Q2 2025 financial results, highlighting progress in its celiac disease program and an unchanged cash runway into 2027.

Barinthus Biotherapeutics reported Q2 2025 financial results, highlighting progress in its Phase 1 AVALON celiac disease trial and a decrease in cash reserves.

Barinthus Biotherapeutics plc announced that all proposed resolutions, including the re-election of directors and re-appointment of auditors, were approved by shareholders at its 2025 Annual General Meeting held on June 10, 2025.

Barinthus Biotherapeutics plc announced its Q1 2025 financial results, provided a corporate update, and highlighted progress in its clinical programs, including VTP-1000 for celiac disease and VTP-300 for chronic hepatitis B.

Barinthus Biotherapeutics announces its 2024 financial results, highlighting a strategic shift towards immunology and inflammation, progress in clinical trials, and a cash runway into 2027.

Barinthus Biotherapeutics is restructuring to focus on immunology and inflammation, prioritizing its celiac disease program and extending its cash runway to the start of 2027.

Barinthus Biotherapeutics has announced the promotion of Geoffrey Lynn to Chief Scientific Officer, succeeding Nadge Pelletier who is stepping down effective February 2, 2025.

Barinthus Biotherapeutics reports positive data from its Phase 2 trials for chronic hepatitis B, showing increased rates of HBsAg loss and functional cures with its VTP-300 immunotherapy.

Barinthus Biotherapeutics reported its third quarter 2024 financial results, highlighted by a $15 million revenue boost and progress in its clinical trials for hepatitis B, celiac disease, and prostate cancer.

Barinthus Biotherapeutics has promoted its Chief Business Officer, Graham Griffiths, to Chief Operating Officer, effective September 1, 2024.

Barinthus Biotherapeutics announced its Q2 2024 financial results and a strategic shift to prioritize its hepatitis B and celiac disease programs following positive clinical trial data.

Barinthus Biotherapeutics is prioritizing its pipeline to focus on VTP-300 for chronic Hepatitis B and VTP-1000 for celiac disease, leading to a 25% workforce reduction and extended cash runway.

Barinthus Biotherapeutics announced positive interim data from two clinical trials of its VTP-300 therapy for chronic hepatitis B, demonstrating significant reductions in viral load and potential for treatment discontinuation.

Barinthus Biotherapeutics held its 2024 Annual General Meeting on May 10, 2024, where all proposed resolutions were approved, including the re-election of directors and the appointment of auditors.

Barinthus Biotherapeutics announced its first quarter 2024 financial results and provided an update on its clinical development programs, including progress in celiac disease, HPV, and hepatitis B.

Barinthus Biotherapeutics announced its first quarter 2024 financial results and provided an update on its clinical development programs, including progress in celiac disease, HPV, and hepatitis B.

Barinthus Biotherapeutics' APOLLO trial of VTP-200 for HPV infections met its primary safety endpoint, showing positive trends in high-dose groups but no statistically significant improvement overall compared to placebo.

Barinthus Biotherapeutics announced its full year 2023 financial results, highlighting clinical progress and a strategic shift in focus.